Corporate trademark excellence has been celebrated at Singapore’s Gardens by the Bay, with the winners of this year’s WTR Industry Awards announced at an exclusive champagne reception.
The court found, among other things, that “pharmaceutical products” in Class 5 and “medical devices” in Class 10 were not complementary.
Back-end work continues to improve the registry and trademark landscape. Subsequently, there has been a noticeable uptick in local brands pushing for the protection of their rights.
11 September 2020
WTR is now seeking nominations for the WTR Industry Awards 2021 and next edition of WTR 300: The World’s Leading Corporate Trademark Professionals.
10 September 2020
India’s newly-formed Central Consumer Protection Authority has issued extensive guidelines designed to regulate advertising and clamp down on misleading claims and practices.
08 September 2020
In our latest round-up, we look at outrage over a WWE order about names and likenesses, Bumble announcing plans to go public, how counterfeiting remains a problem on Taobao, and much more.
08 September 2020
With e-commerce booming, the global pandemic could provide an opportunity to transform the ways in which IP rights are protected and enforced online.
03 September 2020
In a victory for multinational pharmaceutical company Novartis AG, the Colombian Trademark Office has ordered the cancellation of a trademark owned by GlaxoSmithKline, finding that it had not been used in the relevant class.
03 September 2020
The Economic and Trade Agreement between China and the United States was signed on 15 January 2020.
03 September 2020
A new survey looking to explore why consumers buy counterfeit products provides a number of important takeaways for those seeking to combat fake goods.
02 September 2020
This year's index is the first in 13 years to consider brand value, an important inclusion that will strengthen the argument for the importance of brands to national innovation.
02 September 2020
The Court of Appeal of New Zealand has confirmed that concurrent use of the marks ACTAZIN and ACTIPHEN was likely to cause confusion. In contrast, the Australian Trademarks Office had found that the marks were not deceptively similar.
01 September 2020
Unlock unlimited access to all WTR content
